Discover more near‑term opportunities with better event intelligence.
Fundz combines its own real-time funding and M&A intelligence with executive moves, hiring shifts and other company changes, weighs each signal against your ideal customer profile, and delivers a ranked daily shortlist with the context and decision maker to contact. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Iovance Biotherapeutics raised its revenue guidance for 2026 to $410 million-$420 million, marking a $55 million increase. The company attributes this growth to surging demand for its therapies and expanded treatment network.
Amount Raised
$55 Million
Round Type
Venture
DenverManufacturingBiotechnologyHealth CareTherapeuticsDescription
Iovance Biotherapeutics has increased its full-year 2026 revenue guidance following record product revenue in Q2 2026. The new guidance represents nearly 60% annual revenue growth driven by the demand for its FDA-approved therapy, Amtagvi. The company continues expanding its treatment-center network and manufacturing capabilities. Iovance aims to improve scalability for its approved therapies amid growing commercial evaluations.
Fundz sees it the moment Iovance Biotherapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Iovance Biotherapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.
5 screens from a live account. No signup.